Cordis, the pharmaceutical giant, wants to add to the Chinese market

The core business of Johnson and Johnson, the former head of the cardiovascular sector, has finally settled. Recently, Kantle announced that it has officially completed the acquisition of the Cordis division of the former Johnson and Johnson, after which product integration and a new layout has been launched, of which the Chinese market is high hopes.
"This acquisition brings together two key leaders in the healthcare industry, and the combined and complementary role of the company will ensure that patients and doctors around the world have access to more quality products and services," David Wilson, global president of Cordis, a subsidiary of Kantle, told 21st Century Economics. As
market segment leader, Cordis offers solutions for involving the development and manufacture of vascular technology. Cordis offers diagnostic and interventional products including diagnostic and interventional catheters, balloons, self-expanding stents, guide wires and vascular closure devices.
back in 2011, Johnson and Johnson, which has a large business in cardiac stents and interventional therapy, announced a restructuring of its business, eventually spun off its Cordis business unit. "As the drug stent market matures rapidly, (Johnson and Johnson) has found the ability to help more patients in other areas of cardiovascular disease while promoting the company's growth."
four-and-a-half years, the new owner of Cordis, which is separated from the Johnson and Johnson system, is Kantle, the medical-business giant. Kantle (NYSE: CAH) is understood to be a healthcare company designed to improve the cost-effectiveness of healthcare, with a large pharmacy business in global markets, including China. The company has total assets of more than $103 billion. At this stage, Kantle operates the largest network of radiation drugs in the country, providing products for the early diagnosis and treatment of diseases.
note that the deep roots of Kantle and Cordis in the Chinese market have also raised concerns about where their next China strategy will go.
that Kantle is currently in the Chinese market pharmacy business layout is basically completed. In 2013, Kantle acquired Guangzhou Baiji Xinte Pharmaceutical Chain Co., Ltd., and in October of the same year set up Kantle Pharmacy, the company's overall business in the field of foreign-funded pharmaceutical business ranked first. In the short years since Cordis's division left johnson and Johnson, cardiovascular interventional therapy has emerged in its sub-sectors, including minimally invasivable medicine (00853. HK), Lepu Medical (300003. SZ) and other local competitors.
Up to now, the incidence of coronary heart disease in China has been close to the United States and other developed countries, the number of domestic coronary heart disease patients reached 20 million, the number of new patients each year more than one million, and China's PCI surgery (heart stent surgery) cases have been maintained for many years more than 30% compound growth rate, market capacity is constantly expanding.
, Patrick Holt, President of Cordis Asia Pacific, told 21st Century Economics: "China, as an important part of Cordis' global growth plan, offers many opportunities in a rapidly changing market environment. In keeping with the process of China's health care reform, Cordis is well prepared to make a substantial contribution to the health and health care system of Chinese patients through experience and achievement. (HC Pharmaceutical Industry Network)